Bio-Gate AG Logo

Bio-Gate AG

Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.

BIG1 | F

Overview

Corporate Details

ISIN(s):
DE000BGAG981
LEI:
391200G5LKTIOTZOXP90
Country:
Germany
Address:
Neumeyerstr. 28-34, 90411 Nürnberg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bio-Gate AG is a leading provider of innovative technologies and customized solutions for health and hygiene. The company specializes in developing and applying antimicrobial and antiviral strategies to enhance materials and products. Its core markets include medical technology, where it provides coatings for medical implants and wound dressings to prevent infections. Bio-Gate's technologies are also utilized in derma-cosmetics, veterinary medicine (featuring its MicroSilver BG™ technology), and a range of industrial and consumer goods such as paints, plastics, and textiles, improving safety and adding value to end products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-29 18:39
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.3 KB
2025-09-30 15:07
Earnings Release
Bio-Gate veroffentlicht Halbjahreszahlen und bestatigt den Ausblick fur 2025
German 11.4 KB
2025-09-11 20:04
Share Issue/Capital Change
Bio-Gate AG beschliet und platziert Barkapitalerhohung
German 6.1 KB
2025-08-21 17:58
Director's Dealing
Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen
German 6.0 KB
2025-08-19 17:50
Capital/Financing Update
Bio-Gate AG: Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unte…
German 6.2 KB
2025-08-12 17:40
Director's Dealing
Bio-Gate AG: Thomas Konradt, Zeichnung von Wandelschuldverschreibungen
German 5.9 KB
2025-07-31 21:17
Earnings Release
Bio-Gate veroffentlicht endgultige Zahlen 2024 und gibt positiven Ausblick fur …
German 13.0 KB
2025-06-03 21:13
Capital/Financing Update
Bio-Gate AG beschliet Ausgabe einer Wandelschuldverschreibung unter Ausschluss …
German 8.4 KB
2025-04-08 09:56
Regulatory News Service
Bio-Gate starkt in Nordamerika Prasenz fur den Absatz von Tierpflegeprodukten f…
German 12.9 KB
2025-04-08 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 38.0 KB
2025-02-27 11:09
Regulatory News Service
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-26 11:09
Earnings Release
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhalt in klinisch…
German 14.2 KB
2025-02-21 09:30
Regulatory News Service
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB
2025-02-20 09:30
Earnings Release
Bio-Gate bringt uber Partner weitere Produktlinie zum Schutz von Haut- und Hufa…
German 13.1 KB

Automate Your Workflow. Get a real-time feed of all Bio-Gate AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bio-Gate AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bio-Gate AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.